Adipotide vs Retatrutide
A side-by-side research comparison of Adipotide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | Retatrutide |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | ~2.6 kDa | 5,200 Da (approximate) |
| Half-life | Short (hours) | 6 days |
| Bioavailability | Subcutaneous injection | High (SubQ) |
| Typical dose | Not established for human use | 1-2 mg → titrate up to 12 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.